http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20000076420-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-244 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4015 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1793 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06 |
| filingDate | 1998-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2000-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20000076420-A |
| titleOfInvention | Methods and compositions for modulating responsiveness to corticosteroids |
| abstract | The present invention relates to a method of modulating responsiveness to corticosteroids in a subject. In the method of the present invention, an antagonist that inhibits a target that modulates the production of IFN- [gamma] in a subject is administered with a corticosteroid so that the subject's responsiveness to the corticosteroid is controlled compared to the case where only the corticosteroid is administered to the subject. do. In one embodiment, the antagonist is an IL-18 antagonist. In another embodiment, the antagonist is an interleukin-12 (IL-12) antagonist. In another embodiment, the antagonist is NK cell antagonist. In a preferred embodiment, the antagonist is an inhibitor of caspase protease, preferably an ICE inhibitor. In another preferred embodiment, the antagonist is an anti-IL-12 monoclonal antibody. In another preferred embodiment, the antagonist is an anti-asialo-CM1 antibody or NK1.1 antibody. Other preferred antagonists include phosphodiesterase IV inhibitors and beta-2 agonists. The methods of the present invention can be used for the treatment of inflammatory and immunological diseases and disorders. The invention also relates to a pharmaceutical composition comprising an antagonist antagonist antagonist costeroid and a pharmaceutically acceptable carrier that inhibits a target that modulates the production of interferon-γ (IFN-γ) in a subject. Preferred compositions include ICE inhibitors, corticosteroids and pharmaceutically acceptable carriers. |
| priorityDate | 1997-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 821.